Clinical Effects of Liraglutide in a Real-World Setting in Spain: eDiabetes-Monitor SEEN Diabetes Mellitus Working Group Study
Introduction A limitation with randomized controlled trials is that, while they provide unbiased evidence of the efficacy of interventions, they do so under unreal conditions and in a very limited and highly selected patient population. Our aim was to provide data about the effectiveness of liraglutide treatment in a real-world and clinical practice setting. Methods In a retrospective and observational study, data from 753 patients with type 2 diabetes were recorded through an online tool (eDiabetes-Monitor). Results Mean baseline glycated hemoglobin ($ HbA_{1c} $) was 8.4 ± 1.4% and mean body mass index (BMI) was 38.6 ± 5.4 kg/$ m^{2} $. After 3–6 months of treatment with liraglutide, we observed a change in $ HbA_{1c} $ of −1.1 ± 1.2%, −4.6 ± 5.3 kg in weight and −1.7 ± 2.0 kg/$ m^{2} $ in BMI (p < 0.001 for all). Compared to baseline, there was a significant reduction in systolic blood pressure (−5.9 mmHg, p < 0.001), diastolic blood pressure (−3.2 mmHg, p < 0.001), LDL cholesterol (−0.189 mmol/l, p < 0.001) and triglycerides (−0.09 mmol/l, p = 0.021). In patients switched from DPP-4 inhibitors, liraglutide induced a decrease of −1.0% in $ HbA_{1c} $ (p < 0.001) and a reduction in weight (−4.5 kg, p < 0.001). In patients treated with liraglutide as an add-on therapy to insulin a decrease of −1.08% in $ HbA_{1c} $ (p < 0.001) and a weight reduction of −4.15 kg (p < 0.001) were observed. Conclusion Our study confirms the effectiveness of liraglutide in a real-life and clinical practice setting. Funding Spanish Society of Endocrinology and Nutrition..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
Diabetes therapy - 6(2015), 2 vom: Juni, Seite 173-185 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Mezquita-Raya, Pedro [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| Anmerkungen: |
© The Author(s) 2015 |
|---|
| doi: |
10.1007/s13300-015-0112-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2097482465 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2097482465 | ||
| 003 | DE-627 | ||
| 005 | 20240402081023.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230401s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s13300-015-0112-4 |2 doi | |
| 035 | |a (DE-627)OLC2097482465 | ||
| 035 | |a (DE-He213)s13300-015-0112-4-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 100 | 1 | |a Mezquita-Raya, Pedro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clinical Effects of Liraglutide in a Real-World Setting in Spain: eDiabetes-Monitor SEEN Diabetes Mellitus Working Group Study |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2015 | ||
| 520 | |a Introduction A limitation with randomized controlled trials is that, while they provide unbiased evidence of the efficacy of interventions, they do so under unreal conditions and in a very limited and highly selected patient population. Our aim was to provide data about the effectiveness of liraglutide treatment in a real-world and clinical practice setting. Methods In a retrospective and observational study, data from 753 patients with type 2 diabetes were recorded through an online tool (eDiabetes-Monitor). Results Mean baseline glycated hemoglobin ($ HbA_{1c} $) was 8.4 ± 1.4% and mean body mass index (BMI) was 38.6 ± 5.4 kg/$ m^{2} $. After 3–6 months of treatment with liraglutide, we observed a change in $ HbA_{1c} $ of −1.1 ± 1.2%, −4.6 ± 5.3 kg in weight and −1.7 ± 2.0 kg/$ m^{2} $ in BMI (p < 0.001 for all). Compared to baseline, there was a significant reduction in systolic blood pressure (−5.9 mmHg, p < 0.001), diastolic blood pressure (−3.2 mmHg, p < 0.001), LDL cholesterol (−0.189 mmol/l, p < 0.001) and triglycerides (−0.09 mmol/l, p = 0.021). In patients switched from DPP-4 inhibitors, liraglutide induced a decrease of −1.0% in $ HbA_{1c} $ (p < 0.001) and a reduction in weight (−4.5 kg, p < 0.001). In patients treated with liraglutide as an add-on therapy to insulin a decrease of −1.08% in $ HbA_{1c} $ (p < 0.001) and a weight reduction of −4.15 kg (p < 0.001) were observed. Conclusion Our study confirms the effectiveness of liraglutide in a real-life and clinical practice setting. Funding Spanish Society of Endocrinology and Nutrition. | ||
| 650 | 4 | |a Effectiveness | |
| 650 | 4 | |a Liraglutide | |
| 650 | 4 | |a Real life | |
| 650 | 4 | |a Type 2 diabetes | |
| 700 | 1 | |a Reyes-Garcia, Rebeca |4 aut | |
| 700 | 1 | |a Moreno-Perez, Oscar |4 aut | |
| 700 | 1 | |a Escalada-San Martin, Javier |4 aut | |
| 700 | 1 | |a Ángel Rubio Herrera, Miquel |4 aut | |
| 700 | 1 | |a Lopez de la Torre Casares, Martin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes therapy |d Springer Healthcare, 2010 |g 6(2015), 2 vom: Juni, Seite 173-185 |h Online-Ressource |w (DE-627)632439165 |w (DE-600)2566702-6 |w (DE-576)329830902 |x 1869-6961 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2015 |g number:2 |g month:06 |g pages:173-185 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1007/s13300-015-0112-4 |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_23 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_39 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_60 | ||
| 912 | |a GBV_ILN_62 | ||
| 912 | |a GBV_ILN_63 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_73 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a GBV_ILN_95 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_110 | ||
| 912 | |a GBV_ILN_151 | ||
| 912 | |a GBV_ILN_161 | ||
| 912 | |a GBV_ILN_170 | ||
| 912 | |a GBV_ILN_206 | ||
| 912 | |a GBV_ILN_213 | ||
| 912 | |a GBV_ILN_230 | ||
| 912 | |a GBV_ILN_285 | ||
| 912 | |a GBV_ILN_293 | ||
| 912 | |a GBV_ILN_602 | ||
| 912 | |a GBV_ILN_2014 | ||
| 912 | |a GBV_ILN_2190 | ||
| 912 | |a GBV_ILN_2446 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4037 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4126 | ||
| 912 | |a GBV_ILN_4249 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 912 | |a GBV_ILN_4307 | ||
| 912 | |a GBV_ILN_4313 | ||
| 912 | |a GBV_ILN_4322 | ||
| 912 | |a GBV_ILN_4323 | ||
| 912 | |a GBV_ILN_4324 | ||
| 912 | |a GBV_ILN_4325 | ||
| 912 | |a GBV_ILN_4338 | ||
| 912 | |a GBV_ILN_4367 | ||
| 912 | |a GBV_ILN_4700 | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2015 |e 2 |c 06 |h 173-185 | ||